4//SEC Filing
KIDRON NADAV 4
Accession 0001213900-26-001280
CIK 0001176309other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 5:21 PM ET
Size
10.1 KB
Accession
0001213900-26-001280
Insider Transaction Report
Form 4
KIDRON NADAV
DirectorPresident and CEO
Transactions
- Award
Common Stock
2025-12-31+232,640→ 2,919,238 total - Award
Common Stock
2025-12-31+327,000→ 3,246,238 total - Award
Performance Stock Units
2025-12-31+109,000→ 109,000 total→ Common Stock (109,000 underlying)
Holdings
- 126,000(indirect: By wholly-owned corporation)
Common Stock
Footnotes (3)
- [F1]Represents Restricted Stock Units ("RSUs") that vested in full on January 1, 2026. Each RSU represents the right to receive one share of common stock, par value $0.012 per share ("Common Stock"), of the Issuer.
- [F2]Represents RSUs that will vest in quarterly installments over a three-year period starting January 1, 2026. Each RSU represents the right to receive one share of Common Stock of the Issuer.
- [F3]Each performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock. The PSUs vest upon the achievement of either (i) the Issuer's Common Stock achieving a specified price per share, or (ii) the achievement of the applicable performance criteria.
Documents
Issuer
ORAMED PHARMACEUTICALS INC.
CIK 0001176309
Entity typeother
Related Parties
1- filerCIK 0001351779
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 5:21 PM ET
- Size
- 10.1 KB